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OBJECTIVES We sought to assess tenascin-C (TN-C) expression and its possible pathobiological impact in
human aortic valve stenosis.
BACKGROUND Tenascin-C, a large extracellular matrix glycoprotein, has lately been increasingly connected
to cardiovascular pathologies. As TN-C is a multifunctional protein implicated in cell
proliferation, migration and differentiation, we investigated the pattern of its expression in
diseased human aortic valves.
METHODS Fifty-five tricuspid, non-rheumatic stenotic aortic valves were collected from patients
undergoing aortic valve replacement, and the controls consisted of four normal valves from
individuals who had suffered traumatic death and one from a patient operated on because of
a noncalcified purely regurgitant valve. A monoclonal mouse antibody to human TN-C
(143DB7) was used as the primary antibody in immunostaining. To study the source of
TN-C messenger RNA synthesis, some tissue samples were also examined using in situ
hybridization. In order to identify smooth muscle cell differentiation, commercially available
antibodies against alpha-smooth muscle actin were used, and immunophenotypic analysis of
inflammatory cells was carried out by using the monoclonal mouse antibodies UCHL-1, L26
and PGM-1.
RESULTS In normal valves, TN-C expression was associated with the basement membrane beneath the
endothelial cells, whereas stenotic valves showed no such expression but rather immunore-
activity in the deeper layers of the valves. This reactivity was associated with the characteristics
typical of the stenosing process and the increased mechanical loading caused by hypertension.
CONCLUSIONS We hypothesize that the overexpression of TN-C in stenotic human aortic valves may
emphasize that this disease is an active rather than a degenerative process. (J Am Coll
Cardiol 2002;39:96–101) © 2002 by the American College of Cardiology
The pathobiology of non-rheumatic aortic valve stenosis has
changed over time, and recent observations have suggested
that the development of the disease might be actively
regulated and, thus, potentially modifiable, rather than
being an inevitable consequence of aging (1). New evidence
suggests that the molecular mechanisms and cellular com-
ponents leading to valve calcification may resemble those of
bone formation. Extracellular bone matrix proteins (os-
teopontin, osteocalcin and osteonectin) have been identified
in diseased valves (2,3). Inflammatory cells, including mac-
rophages and lymphocytes, are another distinct feature of
valve mineralization (1). Recently, Mohler et al. (4) identi-
fied a population of valvular interstitial cells with osteoblast-
like characteristics that spontaneously formed calcific nod-
ules in cell culture.
Tenascin-C (TN-C) is a modular and multifunctional
hexameric extracellular matrix (ECM) glycoprotein impli-
cated in cell proliferation, migration, differentiation and
apoptosis (5). Tenascin-C expression is less abundant in
normal adult tissues but is induced in malignant tumors and
during inflammation and tissue repair. Tenascin-C expres-
sion has also been increasingly documented in vascular
diseases, and very recent evidence suggests that there may be
a link between protein expression and the development of
calcific aortic stenosis (6).
In the present study, we sought to determine the pattern
of expression of TN-C in human non-rheumatic aortic
valve stenosis. Tenascin expression was closely associated
with the progression of the disease, and, based on TN-C’s
multifunctional properties, the results obtained give further
confirmation that the stenosing process is more likely to be
an active, rather than passive, process.
METHODS
Patients. Fifty-five tricuspid, non-rheumatic stenotic aor-
tic valves were collected from patients (24 men and 31
women with a mean age of 71 years, range: 57 to 82 years)
undergoing aortic valve replacement because of valvular
stenosis. Some of the patients underwent surgery because of
isolated valve stenosis, while some with milder valve pathol-
ogy underwent a combined procedure, usually including
coronary bypass grafting (18/55), which enabled us to
obtain a relatively comprehensive range of disease condi-
tions. The most frequent comorbidities were hypertension
(30/55) and coronary artery disease (28/55). Five normal
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valves were collected to serve as controls; four from individ-
uals who had suffered traumatic death and one from a
patient operated on because of a noncalcified, purely regur-
gitant valve. Macroscopic disease severity was classified as
mild (n 12) (opaque leaflets with focal areas of thickening
and stiffness, mean transvalvular Doppler gradient 30 mm
Hg), moderate (n  23) (more distinct stiffness with
emerging signs of calcification and clinically mild obstruc-
tion, mean gradient 30 to 70 mm Hg) or severe (n  20)
(definite areas of calcification, prominent cusp thickening
and clinically pronounced obstruction, mean transvalvular
gradient 70 mm Hg). Immediately after excision, the
valves were fixed in formaldehyde and embedded in paraffin.
Histologic and immunohistochemical analyses were made
on the samples taken vertically through the leaflet near the
central part.
Immunohistochemistry of TN-C. Sections 5 m thick
were deparaffinized in xylene and rehydrated in a graded
series of alcohol dilutions. Endogenous peroxidase was
consumed by treatment with 0.3% hydrogen peroxide in
absolute methanol for 30 min. A monoclonal mouse anti-
body (Mab) to human tenascin (143DB7) was used as the
primary antibody in TN-C immunostaining. The sections
were incubated with the primary antibody (dilution 1:1000)
at 4°C overnight, followed by biotinylated rabbit anti-mouse
antibody (dilution 1:300) and ABC-complex (Dakopatts,
Glostrup, Denmark). The color was developed with diami-
nobenzidine, whereafter the sections were mounted in an
aqueous medium. The sections were counterstained with a
light hematoxylin stain. In negative controls we substituted
PBS (140 ml NaCl, 0.01 M phosphate buffer, pH 7.2) and
normal mouse serum for the primary antibody.
TN-C in situ hybridization. A complementary DNA
(cDNA) fragment (bases: 814 to 1,316) of full-length
tenascin cDNA was synthesized by polymerase chain reac-
tion (PCR) from a subclone HT-11 kindly provided by Dr.
Luciano Zardi (Instituto Nazionale Per La Ricerca Sul
Cancro, Genova, Italy) using the following primers:
5 CCCTGCAGTGAGGAGCACGGCACA 3,
5 TGCCCATTGACACAGCGGCCATGG 3.
The cDNA (503 base pair) obtained by PCR was
subcloned into a TA vector (TA Cloning Kit, Invitrogen
Inc., Groningen, The Netherlands). Sense and antisense
RNA probes were generated from a linearized template by
using a riboprobe transcription kit (Promega, Madison,
Wisconsin), and the probes were labeled with 35S-UTP
(Amersham International, Buckinghamshire, United King-
dom) to a specific activity of more than 3  108. The
hybridization, the post-hybridization washes and the detec-
tion of hybrids have been described previously (7).
Immunohistochemistry of cellular composition. In order
to identify smooth muscle cell differentiation in the fibro-
blast type cells, commercially available antibodies against
alpha-smooth muscle actin (Clone 1A4, Sigma Biosciences,
St. Louis, Missouri) were used at a dilution of 1:1000. For
an immunophenotypic analysis of inflammatory cells,
monoclonal mouse antibodies UCHL-1, L26 and PGM-1
(Dako, Glostrup, Denmark) were carried out. The
UCHL-1 antibody stains T-cells; L26 stains B-cells, and
PGM-1 stains macrophages. All these antibodies were used
at a dilution of 1:50.
We assessed the extent of inflammation, fibrosis and
calcification in the valves as follows: the extent of inflam-
mation was semiquantified as none, mild (), moderate
() or severe () according to the number of inflam-
matory cells. The inflammatory infiltrate was considered
mild if only a few scattered lymphocytes could be seen in
valvular tissues, mainly in high-power fields. It was consid-
ered moderate if lymphocytes were easily detected in low-
power fields. The lymphatic infiltrate was considered severe
if the lymphocytes formed well-recognized groups of in-
flammatory cells in quantities exceeding 50 cells/HPF.
Fibrosis and calcification were considered mild () if
25%, moderate () if 25% to 50% and severe () if
50% of the valvular area contained fibrotic or calcific
tissues.
Statistical analysis. SPSS 9.0 for Windows (Chicago,
Illinois) was used for statistical analysis. The significances
were determined by Fisher exact test. Significance was
assumed at p  0.05.
RESULTS
Histologic features of the valves. In undiseased valves, the
pars fibrosa was dominated by dense and relatively well-
organized collagen bundles. Within this collagen network,
occasional elongated fibroblast-like cells were observed. The
spongiosa layer consisted of loose, apparently collagen-poor
connective tissue, which was slightly more cell-rich than the
pars fibrosa. Stenotic valves, however, showed subendothe-
lial thickening caused by a combination of interstitial
fibrosis, an accumulation of basal calcified deposits and an
infiltration of inflammatory cells, and the transmural disor-
ganization of valve architecture was characterized by lipid
accumulation, collagen fiber disarray and calcified nodules.
In some cases between the endothelium and a calcium
nodule, distinct heterotopic ossification was seen, and a
distinctly visible cement line attaching the heterotopic bone
to the calcium nodule was detected (Fig. 1A). Within valve
tissue, numerous small vessels were seen, and this feature
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was more striking in the moderate-to-severe forms of valve
pathology (Fig. 1B).
Immunohistochemistry of TN-C and cellular composi-
tion. Tenascin-C immunoreactivity (///)
was seen in undiseased valves as a basement-membrane-
associated zone beneath the endothelial cells (EC) (Fig.
1C). In stenotic valves such expression was lacking, but a
strong reaction was seen in the deeper parts of the valves,
especially adjacent to the calcified areas (Fig. 1B and 1D).
In view of the degree of valve pathology, TN-C induction
was more prominent in the group with severe alterations
compared with the groups with mild or moderate changes
(p  0.006 and p  0.031, respectively) (Fig. 2), and,
accordingly, immunostaining was related to the extent of
calcification, angiogenesis and fibrosis (p  0.031, p 
0.013 and p 0.023, respectively). Furthermore, expression
was more abundant in hypertensive, rather than in normo-
tensive, subjects (p  0.015). Areas with pronounced
inflammation tended to express more TN-C (p  0.07).
The majority of such inflammatory cells expressed a T
phenotype and, to a lesser degree, a B phenotype. The
association of T and B cells with TN-C immunoreactivity
was suggestive (p  0.08, p  0.06, respectively). A similar
tendency was observed with regard to the quantity of
CD68-positive macrophages (p  0.06). Some of the
osteoclast-type cells observed in calcific nodules were also
CD68-positive.
Fusiform alpha-smooth muscle actin-positive cells could
be seen in all the cases studied. The number of these cells was
frequently and profoundly increased in proportion to the
degree of valvular pathology and TN-C expression (Fig. 1E).
TN-C in situ hybridization. In 12 selected cases, TN-C
in situ hybridization experiments were performed. The
messenger RNA (mRNA) signals for TN-C in the control
valves were comparatively weak in most cases, but, in stenotic
valves, increased TN-C mRNA expression was detected in
individual stromal cells, whose positivity for alpha-smooth
muscle actin suggested a myofibroblast phenotype (Fig. 1F).
Figure 1. (A) A decalcified histologic section of an aortic valve stained with hematoxylin-eosin. Eosin-stained dystrophic bone is seen between the
endothelial lining of the valve and the calcium nodule in the lower part of the image. A cement line joins the ossification to the calcium nodule. Dystrophic
bone is marked with an arrow. Scale bar  100 m. (B) Intense tenascin-C (TN-C) immunostaining (arrows) can be seen in the vicinity of the calcified
areas (marked with an asterisk) of the stenotic valve. Notice the inflammatory cells and the neovascularization (arrowheads) in the right corner of the field.
(C) TN-C immunoreactivity can be seen as a basement membrane-associated zone in undiseased valves (arrow). The valvular stroma is otherwise negative.
(D) Around the areas of calcification (asterisk) in a stenotic valve, intense TN-C immunopositivity (arrows) can be seen. Linear basement
membrane-associated staining is missing. (E) Immunostaining with an antibody to alpha-smooth muscle actin. Strong positivity for this antigen can be seen
in stromal fibroblast-type cells, suggesting myofibroblastic differentiation of the cells. (F) In situ hybridization of a stenotic valve. Strong signals for tenascin
(arrows) can be seen in fusiform fibroblast-like cells in the stroma.
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DISCUSSION
Major findings. This report provides with a comprehensive
clinical series the first description of TN-C expression in
human aortic valves. We found three novel features: 1)
TN-C expression in normal valves was associated with the
basement membrane beneath the ECs; 2) stenotic valves
showed no such expression but showed immunoreactivity in
the deeper layers of the valves, especially in calcific nodules;
and 3) the positivity of TN-C staining in diseased cases was
closely associated with the characteristics typical of the
stenosing process. The main source of TN-C production in
diseased valves seemed to be stromal myofibroblasts. In the
control valves, TN-C mRNA signals were noticeably weak,
which may suggest that the mRNA level required for
maintaining a suitable protein concentration in tissues is
low.
Potential mechanisms for TN-C upregulation. A num-
ber of factors may have led to the upregulation of TN-C
expression observed here. For example, the basic fibroblast
growth factor, which stimulates TN-C synthesis in other
cell types, may be liberated in a bioactive form from the
myofibroblast ECM stores by serine elastases (8). Given
that increased serine elastase activity is observed in aortic
valve lesions (6,9), it is possible that these enzymes induce
TN-C expression. The stromal recruitment of mononuclear
inflammatory cells and their suggestive association with
TN-C possibly indicate that the soluble factors produced by
these cells may stimulate protein expression, as interleukin-
1beta has been shown to induce TN-C in a variety of cell
types, including interstitial valvular cells (8). Further, the
induction of a more homogenous pattern of expression of
TN-C in progressive disease may be related to the paracrine
induction of expression, which has been documented in
vascular and other pathologies (10). This assumption is
supported by the fact that interleukin-1 has been shown to
play a role in the progression of pulmonary hypertension in
monocrotaline-treated rats.
Since the increased expression of TN-C correlated tem-
porally with the development and progression of the valvular
lesions, especially under an increased hemodynamic loading,
mechanical factors should also be considered. Mechanical
forces are known to induce TN-C in neonatal rat cardiac
myocytes in an amplitude-dependent manner (11). Chick
embryo fibroblasts, vascular smooth muscle cells and whole
pulmonary arteries cultured on attached (stretched) type I
collagen substrates produce higher levels of TN-C than
those cultivated on mechanically relaxed collagen gels
(12,13). Similarly, the hemodynamic stress of increased
arterial pressure induces TN-C expression in saphenous
vein grafts interposed into arterial circulation (14). Mechan-
ical pressure causes a redistribution of TN-C in scar tissue,
and the increased pulmonary blood flow and the concomi-
tantly increased strain exerted on vascular smooth muscle
cells within the pulmonary arterial wall also lead to in-
creased TN-C production in vivo (8). Collectively, the
altered biomechanics may potentially account for the ap-
pearance of TN-C in tissues, where it is believed to play a
regenerative or morphoregulatory role and may, therefore,
elaborate the progressive lumen-to-media-directed protein
induction detected in hypertensive patients with valve ste-
nosis.
Pathobiological aspects on valvular stenosis. As regards
its multifunctional properties, TN-C may have certain
consequences for the pathogenesis of aortic valve stenosis.
With respect to calcification, the present findings provided
evidence that calcific nodules resembling heterotopic bone
Figure 2. Tenascin-C expression presented in percentages in relation to the degree of valve pathology.
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were involved by TN-C. Cells of the osteoblast lineage are
known to express TN-C from the onset of osteogenesis
onwards, and TN-C can then modulate osteoblast behavior
by stimulating cell differentiation and functional state (15).
Tenascin-C, in transforming growth factor-beta-treated
(TGF-beta) bone cells, is known to stimulate bone forma-
tion by mediating the osteogenic effects of TGF-beta in
bone (16). The mechanical stress on TN-C and the calci-
fication, the physical loading and the resulting increased
strain imposed on rat ulnae lead to early increases in
osteoblast TN-C expression, indicating that this protein
may act as a mediator of osteoregulatory responses to altered
biomechanics (17). Further, in vivo studies of TN-C ex-
pression in fibroblasts and chondrocytes within the osteo-
tendinous junction under mechanical stress revealed a con-
temporaneous increase in both protein expression and
ectopic ossification (18). Hence, we can postulate that
TN-C may mediate the signal of increased hemodynamic
stress as regards ossific alterations in valve tissue and that the
calcific process is physiological, rather than degenerative, in
nature.
Normal semilunar aortic valve cusps are sufficiently thin
to allow complete nutrition by diffusion, and they are nearly
avascular, although some investigators have described small
blood vessels limited to the cuspal bases (19). In this study,
diseased valves showed variable angiogenic changes, which
were most obvious in moderate-to-severe forms of the
disease and were significantly associated with TN-C expres-
sion. Angiogenesis is an important event in a variety of
physiological settings, but it is also central to the etiology of
a number of pathologic processes. Angiogenesis requires the
breakdown and reassembly of the ECM, migration and
proliferation of ECs and endothelial tube formation, and it
is driven by a cocktail of growth factors and proangiogenic
cytokines and tempered by an equally diverse group of
inhibitors. In this regard matrixmetalloproteinases (MMP)
have also received substantial attention. Type IV collage-
nase, also called MMP-2, can help degrade the subendo-
thelial basement membrane starting the formation of a new
channel. Jian et al. (6) in their recent work showed that
TN-C has an important impact in the upregulation of both
MMP-2 expression and its gelatinolytic activity. Interac-
tions between cells and ECM molecules are mediated by
cellular receptors, and TN-C is of particular interest in this
connection because it binds to several integrins, including
alpha2beta1 and alphavbeta3, both of which have been
demonstrated to be involved in neovascularization (20).
Furthermore, TN-C is known to be associated with the
sprouting, but not the resting, phenotype of aortic ECs in
vitro, and the angiogenic phenotype is inhibited when cells
are grown in the presence of anti-TN-C antibodies, sug-
gesting that the transition from a resting to a sprouting
phenotype may be promoted by the reduced adhesive
strength produced by TN-C (21).
Chronic inflammation was a common finding in diseased
aortic valves, and the association was parallel to neovascu-
larization and, to a lesser degree, TN-C expression. The
importance of the inflammatory cellular infiltrate may lie in
its potential modulation of endothelial and smooth muscle
cell function through the cytokine network or even suggest
a possible immune-mediated mechanism in valvular pathol-
ogy. The specific factors that initially attract macrophages
and lymphocytes into the valvular stroma remain unknown.
Our results may provide one possible explanation for the
mechanics of cellular accumulation, emphasizing the adhe-
sive function of TN-C. Previous static binding assays have
not confirmed the assumption that peripheral blood cells
adhere to this glycoprotein (5). Two recent studies, how-
ever, have largely settled this matter and explained conclu-
sively the modulation of interaction between lymphocytes
and TN-C, providing further overall characterization of the
adhesive properties of TN-C. First, Gundersen et al. (22)
reported their novel finding that stimulated T lymphocytes
can induce degradation of the ECM protein TN-C by
plasminogen-dependent proteolysis and that this degrada-
tion acts as a feedback mechanism to selectively modulate
the adhesive interaction between T lymphocytes and TN-C.
This observation lent support to the presumption that the
physical integrity of the TN-C molecule may determine its
adhesive or antiadhesive activity and that limited proteolysis
may provide a physiological mechanism mediating this
activity. Contemporaneously with the work of Gundersen,
Clark et al. (23) further pointed out that, under experimen-
tal shear flow conditions, peripheral blood leukocytes and
several cell lines, especially of the T-cell lineage, may show
low-avidity and transient adhesion to TN-C, which results
in tethering and rolling. Taken together, the obvious asso-
ciation of inflammatory cells and TN-C with microcapil-
laries in the stroma of stenotic valves may result in adhesion,
with inflammatory cells rolling along the endothelial sur-
face, and then tight adherence of cells, resulting in immo-
bilization and transmigration across the damaged endothe-
lium into the inner layers via a route provided by these small
vessels.
Summary. We propose that the increased expression of
TN-C in stenotic aortic valves emphasizes the possibility
that, rather than being a degenerative process, aortic valve
mineralization is an active process. Models created in vitro
to manipulate TN-C induction by, for example, using
monoclonal antibodies against human TN-C may serve as
future therapies to prevent and treat calcific valvular disease
based upon the interfering role of TN-C in the mineraliza-
tion mechanism.
Reprint requests and correspondence: Dr. Jari Satta, Depart-
ment of Cardiothoracic Surgery, University of Oulu, Kajaanintie
52 A, FIN-90220 Oulu, Finland. E-mail: jari.satta@oulu.fi.
REFERENCES
1. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the
early lesions of “degenerative” aortic valvular stenosis: histologic and
immunohistochemical studies. Circulation 1994;90:844–53.
100 Satta et al. JACC Vol. 39, No. 1, 2002
TN-C in Aortic Valve Stenosis January 2, 2002:96–101
2. Srivatsa SS, Harrity PJ, Maercklein PB. Increased cellular expression
of matrix proteins that regulate mineralization is associated with
calcification of native human and porcine xenograft bioprosthetic heart
valves. J Clin Invest 1997;99:996–1009.
3. O’Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is
expressed in human aortic valvular lesions. Circulation 1995;92:
2163–8.
4. Mohler ER, Chawla MK, Chang AW, et al. Identification and
characterization of calcifying valve cells from human and canine aortic
valves. J Heart Valve Dis 1999;8:254–60.
5. Jones PL, Jones FS. Tenascin-C in development and disease: gene
regulation and cell function. Matrix Biol 2000;19:581–96.
6. Jian B, Jones PL, Quanyi L, Mohler ER, III, Schoen FJ, Levy RJ.
Matrix metalloproteinase-2 is associated with tenascin-C in calcific
aortic stenosis. Am J Pathol 2001;159:321–7.
7. Autio-Harmainen H, Hurskainen T, Niskasaari K. Simultaneous
expression of 70 kilodalton type IV collagenase and type IV collagen
alpha-1 (IV) chain genes by cells of early human placenta and
gestational endometrium. Lab Invest 1992;67:191–200.
8. Jones FS, Jones PL. The tenascin family of ECM glycoproteins:
structure, function, and regulation during embryonic development and
tissue remodelling. Dev Dyn 2000;218:235–59.
9. Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase
expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000;9:
281–6.
10. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive
pulmonary vascular disease in rats and is functionally related to
increased smooth muscle cell proliferation. Circ Res 1996;79:1131–
42.
11. Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA,
Lee RT. Induction of tenascin-C in cardiac myocytes by mechanical
deformation. J Biol Chem 1999;274:21840–6.
12. Chiquet M, Matthison M, Koch M, Tannheimer M, Chiquet-
Ehrishmann R. Regulation of extracellular matrix synthesis by me-
chanical stress. Biochem Cell Biol 1996;74:737–44.
13. Cowan KN, Jones PL, Rabinovitch M. Regression of hypertrophied
rat pulmonary arteries in organ culture is associated with suppression
of proteolytic activity, inhibition of tenascin-C and smooth muscle cell
apoptosis. Circ Res 1999;84:1223–33.
14. Wallner K, Li C, Fishbein MC, Shah PK, Sharifi BG. Arterialization
of human vein grafts is associated with tenascin-C expression. J Am
Coll Cardiol 1999;34:871–5.
15. Mackie EJ, Ramsey S. Modulation of osteoblast behaviour by tenascin.
J Cell Sci 1996;109:1597–604.
16. Mackie EJ, Abraham LA, Taylor SL. Regulation of tenascin-C
expression in bone cells by transforming growth factor-beta. Bone
1998;4:301–7.
17. Webb CM, Zaman G, Mosley JR, Tucker RP, Lanyon LE, Mackie
EJ. Expression of tenascin-C in bones responding to mechanical load.
J Bone Miner Res 1997;12:52–8.
18. Ja¨rvinen T, Jorza L, Kannus P, et al. Mechanical loading regulates
tenascin-C expression in the osteotendinous junction. J Cell Sci
1999;112:3157–66.
19. Schoen JF. Aortic valve structure-function correlations: role of elastic
fibers no longer a stretch of the imagination. J Heart Valve Dis
1997;6:1–6.
20. Stro¨mblad S, Cheresh DA. Integrins, angiogenesis and vascular cell
survival. Chem Biol 1996;3:881–5.
21. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1
modulate sprouting of endothelial cells. J Cell Sci 1995;108:797–809.
22. Gundersen D, Tran-Thang C, Sordat B. Plasmin-induced proteolysis
of tenascin-C. J Immunol 1997;158:1051–60.
23. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte
rolling. J Cell Biol 1997;137:755–65.
101JACC Vol. 39, No. 1, 2002 Satta et al.
January 2, 2002:96–101 TN-C in Aortic Valve Stenosis
